Dunad Therapeutics develops next-generation small-molecule protein degradation therapies through use of their proprietary screening library and mono-valent degrader platform. Their unique small molecule platform allows for targeted degradation of specific protein targets through the modulation of the protein’s stability and conformation. They aim to produce a pipeline of novel therapeutics for oncology and CNS indications. Their headquarters is located in Cambridge, UK, but they operate in both the UK and North America. Dunad was co-founded in 2020 by Patrick T. Gunning has received nineteen research awards, including Canada’s Top 40 under 40 award.

Dunad Therapeutics

Founded: 2020
Location: London, UK
Employee range: 11 - 50
Clinical stage: RD
Therapy area: Oncology
Drug types: ONC, NEU
Lead product: Undisclosed

Drug notes:

About:

Jobs: